Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
5 participants
INTERVENTIONAL
2012-10-01
2013-07-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
One Touch® Verio®IQ European Clinical Outcomes Study
NCT01631643
Project VerioVue Enhancements - Arterial Study
NCT06121856
OneTouch Verio Flex System Accuracy Evaluation
NCT03138174
Bias Source of Signal in SCOUT DS
NCT01550328
OM2 Abbreviated Sensor Verification
NCT06415799
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
VerioIQ
Subjects replaced own Blood Glucose Monitoring system with VerioIQ.
One Touch VerioIQ Blood Glucose Monitor
BGM with pattern alert technology and with associated pattern guide
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
One Touch VerioIQ Blood Glucose Monitor
BGM with pattern alert technology and with associated pattern guide
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ADA guidelines for FPG and PPG appropriate
* A1C greater or equal to 8.0% and less than or equal to 10.5%
* lab A1C greater than or equal to 8.0% in the last 6-12mths
* Diagnosed with type 1 or 2 in at least last 1 year
* on stable dose of OADs for at least 3mths prior to screening
* willingness to test 7 BGM tests per day
* willing to remain on same therapy as baseline (MDI) for duration of study
Exclusion Criteria
* has or has currently used One Touch VerioIQ
* Is on fixed doses of insulin for MDI therapy
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
LifeScan
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Priscilla Hollander, MD
Role: PRINCIPAL_INVESTIGATOR
Baylor Endocrine Center, 3600 Gaston Avenue Wadley Tower, Suite 656, Dallas, TX 75246, Phone: 214-820-3466, Fax: 214-820-3468
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
3091611
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.